Isovorin

Calcium levofolinate, the active ingredient in Isovorin, is a folate analog presented as an oral formulation for oral use. It is employed to mitigate the toxic effects of folate antagonists and to support DNA synthesis in normal cells during chemotherapy.\n\nGNH India supplies Isovorin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Isovorin is a folate‑based antineoplastic adjuvant used to protect normal tissues during chemotherapy.\n\n- Methotrexate toxicity: reduces harmful effects of high‑dose methotrexate therapy.\n- High‑dose 5‑fluorouracil (5‑FU) treatment: provides rescue after intensive 5‑FU regimens.\n- Chemotherapy‑induced folate deficiency: supports recovery of normal cell replication during cancer treatment.

Adverse reactions may occur with calcium levofolinate use.\n\nCommon Side Effects:\n- Nausea or vomiting\n- Diarrhea or abdominal discomfort\n- Mild skin rash or itching\n- Transient elevation of liver enzymes\n\nSerious or Rare Side Effects:\n- Severe allergic reaction (anaphylaxis)\n- Bone marrow suppression leading to pancytopenia\n- Acute renal impairment\n- Hepatic dysfunction with jaundice

Use calcium levofolinate with appropriate clinical monitoring.\n\n- Renal function assessment: evaluate kidney status before and during therapy.\n- Hepatic monitoring: check liver enzymes regularly.\n- Folate status review: ensure patient does not have pre‑existing folate deficiency.\n- Hypersensitivity caution: discontinue if severe allergic signs appear.\n- Pregnancy and lactation: safety not established; avoid unless clearly needed.\n- Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Calcium levofolinate may interact with several medications.\n\nMajor Interactions (Avoid):\n- Concurrent high‑dose methotrexate: may diminish rescue effect.\n- Other folate antagonists (e.g., pemetrexed): can increase toxicity.\n- Trimethoprim‑sulfamethoxazole: interferes with folate metabolism.\n\nModerate Interactions (Monitor Closely):\n- Non‑steroidal anti‑inflammatory drugs (NSAIDs): may affect renal clearance.\n- Proton pump inhibitors: possible alteration of absorption.\n- Antacids containing aluminum or magnesium: may reduce bioavailability.\n- Oral contraceptives: monitor for reduced efficacy.